TScan Therapeutics (TCRX) EBITDA (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of EBITDA data on file, last reported at -$29.1 million in Q1 2026.

• On a quarterly basis, EBITDA rose 19.62% year-over-year to -$29.1 million in Q1 2026; TTM through Mar 2026 was -$128.7 million, a 7.87% increase from a year earlier, with the FY2025 full-year figure at -$135.8 million, down 0.74% from the prior year.
• EBITDA for Q1 2026 stood at -$29.1 million, down from -$23.9 million in the prior quarter.
• Over the last five years, EBITDA for TCRX reached as high as -$15.2 million in Q2 2022 and fell as low as -$38.7 million in Q2 2025.
• Historically, EBITDA has averaged -$27.1 million across 5 years, with a median of -$24.7 million in 2023.
• Across the five-year window, EBITDA tumbled 104.13% in 2022 and surged 35.01% in 2025, its largest moves.
• Year by year, EBITDA stood at -$18.6 million in 2022, then slipped by 14.52% to -$21.4 million in 2023, then tumbled by 71.9% to -$36.7 million in 2024, then jumped by 35.01% to -$23.9 million in 2025, then dropped by 22.14% to -$29.1 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$29.1 million in Q1 2026, -$23.9 million in Q4 2025, and -$37.1 million in Q3 2025.